Vectura’s portfolio has emerged from the Company’s product development, formulation and drug delivery expertise and is currently centred around developing inhaled products to address unmet needs in airways diseases.

We continue to focus on balancing the unmet needs of all stakeholders (patients, physicians, payors) with commercial attractiveness and exploiting valuable niches in our therapeutic space.

   Investors

Date: 01/09/2015

Share price summary

1

WE INNOVATE

2

WE DEVELOP

3

WE COLLABORATE

Annual report

AR-15.png

Download annual report

Presentations and webcasts

08 September 2015

J.P. Morgan London Small/Mid Cap Conference, London

18 September 2015

Bank of America Merrill Lynch Global Healthcare Conference 2015, London
Vectura presenting 14:30 BST

02-04 November 2015

Bio Europe 2015, Munich, Germany

View full list